Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) EBT (2016 - 2025)

Assembly Biosciences has reported EBT over the past 11 years, most recently at $22.1 million for Q4 2025.

  • Quarterly results put EBT at $22.1 million for Q4 2025, up 312.18% from a year ago — trailing twelve months through Dec 2025 was -$6.1 million (up 84.64% YoY), and the annual figure for FY2025 was -$6.1 million, up 84.64%.
  • EBT for Q4 2025 was $22.1 million at Assembly Biosciences, up from -$9.2 million in the prior quarter.
  • Over the last five years, EBT for ASMB hit a ceiling of $22.1 million in Q4 2025 and a floor of -$62.8 million in Q4 2021.
  • Median EBT over the past 5 years was -$15.7 million (2023), compared with a mean of -$16.6 million.
  • Biggest five-year swings in EBT: crashed 461.45% in 2021 and later soared 312.18% in 2025.
  • Assembly Biosciences' EBT stood at -$62.8 million in 2021, then skyrocketed by 64.33% to -$22.4 million in 2022, then skyrocketed by 51.2% to -$10.9 million in 2023, then grew by 4.74% to -$10.4 million in 2024, then surged by 312.18% to $22.1 million in 2025.
  • The last three reported values for EBT were $22.1 million (Q4 2025), -$9.2 million (Q3 2025), and -$10.2 million (Q2 2025) per Business Quant data.